Association of a mutation in the RUNX1 gene with the outcome of the disease in acute myeloid leukemia (meta-analysis)
https://doi.org/10.24884/1607-4181-2023-30-2-77-87
Abstract
The article summarizes the data of a systematic review of scientific publications on acute myeloid leukemia over the past 10 years.
The objective was to conduct a meta-analysis of the data published in the open press to investigate the nature of the association of mutations in the RUNX1 gene with the outcome of acute myeloid leukemia.
Methods and materials. The search for publications was carried on library platforms eLibrary.ru, Google Academy, PubMed, Web of Science according to the criteria PRISMA 2020. The selection of studies was carried out using the Rayyan online program. The meta-analysis was performed on the basis of the RStudio application package. The main characteristics in the studies were reflected in overall survival, relapse-free survival, hazard ratio and were assessed by a standardized effect size. The magnitude of the effect was based on the difference between the observed patients and patients with mutations in the RUNX1 gene. The outliers filtering based on the combines confidence interval. The bias of publications was assessed visually and quantitatively.
Results. The search identified 579 publications, 10 were included in the meta-analysis, the total sample was 2733 patients. The results of statistical tests on the Cochran Q-test (p-value < 0.0001) and the Higgens–Thompson test (92 %) indicate a high heterogeneity of the included publications. The variance of heterogeneity together with the 95 %CI (0.177; 1.528) indicates the heterogeneity of the research results. The combined 95 %CI (0.47; 2.90) does not suggest that mutations in the RUNX1 gene always lead to a poor prognosis. Egger’s regression test (p-value > 0.098) showed no publication bias.
Conclusion. The results of the study revealed a statistical relationships between the influence of mutations in the RUNX1 gene and the outcome of the disease.
Supporting agencies: The authors would like to express their gratitude to the scientific supervisor Artem V. Tishkov, Ph. D. of Physico-mathematical Sciences, Docent, Head of the Department of Physics, Mathematics and Informatics for significant comments and advices in conducting research and formatting the article. The authors would like to express their gratitude to Ildar M. Barkhatov, leading research fellow of the Department of Clinical Oncology, Head of the Laboratory of Transplantation and Molecular Hematology of the R. M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantology for cooperation, significant comments and advice in preparing the results of scientific research for publication.
About the Authors
M. L. Nikonorova
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Nikonorova Margarita L., Dr. of Sci. (Pedagogic), Associate Professor of the Department of Physics, Mathematics and Informatics
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest
L. K. Kats
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Kats Leonid K., 3nd year Student, Laboratory Assistant of the Department of Physics, Mathematics and Informatics
Saint Petersburg
Competing Interests:
Authors declare no conflict of interest
References
1. Tuo Z., Zhang Y., Wang X., Dai S., Liu K. et al. RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers // BioMed Central Cancer. 2022;22(1):523. DOI: 10.1186/s12885-022-09632-y.
2. Yu J., Li Y., Zhang D., Jiang D., Wan, D., Jiang Z. Clinical implications of recurrent gene mutations in acute myeloid leukemia // Experimental Hematolgy & Oncology. 2020;9(1):4. DOI: 10.1186/s40164-020-00161-7.
3. Jalili M., Yaghmaie M., Ahmadvand M., Alimoghaddam K., Mousavi S. A. et al. Prognostic value of RUNX1 mutations in AML: a meta-analysis // Asian Pacific Journal of Cancer Prevention. 2018;19(2):325–329. DOI: 10.22034/APJCP.2018.19.2.325.
4. Tang J. L., Hou H.A., Chen C.Y., Liu C.Y., Chou W. C. et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations // Blood. 2009;114(26):5352– 5361. DOI: 10.1182/blood-2009-05-223784.
5. Greif P. A., Konstandin N. P., Metzeler K. H., Herold. T., Pasalic Z. et al. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with poor prognosis and up-regulation of lymphoid genes // Haematologica. 2012; 97(12):1909–1915. DOI: 10.3324/haematol.2012.064667.
6. Gaidzik V. I., Bullinger L., Schlenk R. F., Zimmermann A. S., Röck J. et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group // Journal of Clinical Oncology. 2011;29(10):1364–1372. DOI: 10/1200/jco.2010.30.7926.
7. Motyko E. V., Blau O. V., Polushkina L. B., Martynenko L. S., Bakaj M. P. et al. Molecular genetic profile of 620 patients with acute myeloid leukemia, assessment of the im-1. Tuo Z., Zhang Y., Wang X., Dai S., Liu K. et al. RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers // BioMed Central Cancer. 2022;22(1):523. DOI: 10.1186/s12885-022-09632-y.
8. Kashlakova A. I., Parovichnikova E. N., Biderman B. V., Sidorova Yu. V., Chabaeva Yu. A. et al. Next-generation sequencing-based molecular genetic profiling in adults with acute myeloid leukaemia // Hematology and transfusiology. 2020;65(4):444–459. (In Russ.). DOI: 10.35754/0234-5730-2020-65-4-444-459.
9. Malygina O. G., Makarova A. A., Usynina A. A. The gut microbiota and infant’s neurodevelopment: an example of systematic review methodology application // Modern problems of science and education. 2022;(2):88–88. (In Russ.). DOI: 10.17513/spno.31575.
10. Page M. J., Moher D., Bossuyt P. M., Boutron I., Hoffmann T. C. et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews // BMJ. 2021;372:n160. DOI: 10.1136/bmj.n160.
11. Page M. J., McKenzie J. E., Bossuyt P. M., Boutron I., Hoffmann T. C. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews // BMJ. 2021;372:n71. DOI: 10.1136/bmj.n71.
12. Belocerkovskaja E. V., Zajkova E. K., Petuhov A. V., Demidov O. N., Levchuk K. A. et al. Identification of mutations in IDH1/2, DNMT3A, ASXL1 genes of genome epigenetic regulation and their co-occurrence with FLT3, NPM1, RUNX1 mutations in acute myeloid leukemia // Clinical oncohematology. Basic research and clinical practice. 2021; 14(1):13–21. (In Russ.). DOI: 10.21320/2500-2139-2021-14-1-13-21.
13. Metzeler K. H., Herold T., Rothenberg-Thurley M., Amler S., Sauerland M. C. et al. AMLCG Study Group. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia // Blood. 2016;128(5):686–698. DOI: 10.1182/blood-2016-01-693879.
14. Jahn N., Jahn E., Saadati M., Bullinger L., Larson R.A. et al. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/ RATIFY trial // Leukemia. 2022;36(9):2218–2227. DOI: 10.1038/s41375-022-01650-w.
15. Herold T., Metzeler K. H., Vosberg S., Hartmann L., Röllig C. et al. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis // Blood. 2014;124(8):1304– 1311. DOI: 10.1182/blood-2013-12-540716.
16. Sakamoto K., Shiba N., Deguchi T., Kiyokawa N., Hashii Y. et al. Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1 – positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study // British Journal of Haematology. 2019; 187(3):372–376. DOI: 10.1111/bjh.16080.
17. Cheng Z., Dai Y., Pang Y., Jiao Y., Zhao H. et al. Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M0 and M1 // Cellular Physiology Biochemistry. 2018;47(5):1853–1861. DOI: 10.1159/000491065.
18. Yu J., Li Y., Li T., Li Y., Xing H. et al. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia // Experimental Hematology & Oncology. 2020;9:2. DOI: 10.1186/s40164-019-0158-5.
19. Venugopal S., DiNardo C. D,. Loghavi S., Qiao W., Ravandi F. et al. Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia // American Journal of Hematoogyl. 2022; 97(12):1560–1567. DOI: 10.1002/ajh.26724.
20. Liu J., Han W., Cai X., Wang Z., Cao L. et al. Molecular genetic and clinical characterization of acute myeloid leukemia with trisomy 8 as the sole chromosome abnormality // Hematology. 2022;27(1):565–574. DOI: 10.1080/16078454.2022.2071799.
21. Hopkins W. G. A new view of statistics. Victoria University, Melbourne (Australia), 2013. URL: http://www.sportsci.org/resource/stats/ (accessed: 10.10.23).
22. Harrer M., Cuijpers P., Furukawa T. A., Ebert D. D. doing meta-analysis with R: a hands-on guide (1st ed.). New York, Chapmann & Hall/CRC, 2021:500. DOI: 10.1201/9781003107347.
23. Rothstein H. R., Sutton A. J., Borenstein M. Publication bias in meta-analysis (1st ed.). New York, John Wiley & Sons, 2005. DOI: 10.1002/0470870168.
24. Egger M., Davey Smith G., Schneider М., Minder С. Bias in meta-analysis detected by a simple, graphical test // BMJ. 1997;315(7109):629–634. DOI: 10.1136/bmj.315.7109.629.
Supplementary files
Review
For citations:
Nikonorova M.L., Kats L.K. Association of a mutation in the RUNX1 gene with the outcome of the disease in acute myeloid leukemia (meta-analysis). The Scientific Notes of the Pavlov University. 2023;30(2):77-87. (In Russ.) https://doi.org/10.24884/1607-4181-2023-30-2-77-87
Views:
444
Email this article 